FTC staff signs off on Roche $4.3B deal for Spark — re­port

Roche is one step clos­er to reg­u­la­to­ry en­dorse­ment — in the form of an FTC staff rec­om­men­da­tion — to buy Spark Ther­a­peu­tics with­out any as­set sales, ac­cord­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER